Caraco Recalls Cephalexin Capsules Due to Manufacturing Practice Deviations
Caraco Pharmaceutical Laboratories is recalling Cephalexin Capsules, 500 mg, because they were manufactured with active pharmaceutical ingredients that did not follow good manufacturing practices.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, and the source text does not report any illnesses, injuries, or hospitalizations, fitting the criteria for a moderate severity score.
Plain-English summary
Caraco Pharmaceutical Laboratories, Ltd. is recalling Cephalexin Capsules, USP, 500 mg, packaged in 100-count and 500-count bottles. The affected products are prescription-only and were manufactured by Sun Pharmaceutical Ind. Ltd. in India.
The recall was initiated because the products were manufactured with active pharmaceutical ingredients (APIs) that were not manufactured with good manufacturing practices (CGMP deviations). The affected lots were distributed nationwide and in Puerto Rico.
Consumers and healthcare providers should stop using the affected Cephalexin Capsules and contact their healthcare provider for a replacement or alternative treatment. The specific lot numbers and expiration dates are detailed in the official recall notice.
The recalled product
- Product
- Cephalexin Capsules, USP, 500 mg, packaged in a) 100-count bottles (NDC 62756-294-88) and b) 500-count bottles (NDC 62756-294-13), Rx only, Manufactured by: Sun Pharmaceutical Ind. Ltd., Acme Plaza, Andheri-Kurla Road, Andheri (East), Mumbai-400 059, India.
- Manufacturer
- Caraco Pharmaceutical Laboratories, Ltd.
- Category
- Drug — Antibiotic
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot #: a) AGL0058B
- AGL0059B
- AGL0060B
- AGL0061B
- Exp 06/14
- AGL0062B
- AGL0063B
- AGL0064B
- Exp 07/14
- AGL0083B
- AGL0084B
- AGL0085B
- AGL0086B
- AGL0087B
- AGL0088B
- AGL0089B
- AGL0090B
- Exp 08/14
- AGL0120B
- AGL0121B
Distribution
Part of a larger recall action
This product is one of 2 recalled by Caraco Pharmaceutical Laboratories, Ltd. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Caraco Pharmaceutical Laboratories, Ltd.
See all →- ModerateCaraco Recalls Cephalexin Capsules Due to Manufacturing Deviations
FDA (Drugs) · 2014-08-13
- ModerateCaraco Recalls Venlafaxine Hydrochloride Extended-Release Tablets for Dissolution Failures
FDA (Drugs) · 2014-07-09
- SevereCaraco Recalls Gemcitabine Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-07-02
- ModerateCaraco Recalls Venlafaxine Hydrochloride Extended-Release Tablets for Dissolution Failures
FDA (Drugs) · 2014-05-07
- ModerateCaraco Recalls Children's Cetirizine Tablets Due to Impurity Failures
FDA (Drugs) · 2014-05-07
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- SevereShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19